A comprehensive review being published in Annals of Internal Medicine looks at the latest evidence on drugs for patients with low bone density. Various pharmaceuticals are available to treat osteoporosis and questions remain about comparative effectiveness, optimal duration of therapy, and adverse events.
Researchers conducted a systematic review of 294 articles to update a 2007 review on the benefits and harms of pharmacological treatments used to prevent fractures in adults with low bone density. While few studies directly compared different drugs used to treat osteoporosis, strong evidence suggests that several low bone density drugs, including bisphosphonates, denosumab, and teriparatide, are safe and effective for reducing fractures in at-risk patients. Optimal treatment duration and side effects profiles varied among treatments.
Results and Discussion:
The authors of an accompanying editorial (http://www.annals.org/article.aspx?doi=10.7326/M14-2006) write that the clear reporting on side effects provided in the current review will help physicians make informed decisions about treatments. However, they caution that the reviewers’ conclusions may not apply to persons aged 75 or older with nonskeletal risk factors for fracture because this population is insufficiently represented in current clinical trials.
Annals Of Internal Medicine
The lead author may be contacted through Enrique Rivero at firstname.lastname@example.org or 310-794-2273.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.